- Or histologically or cytologically confirmed estrogen receptor (ER) positive and HER-2 negative metastatic breast cancer are eligible if they have progressed on single agent or combination endocrine therapy (e.g. aromatase inhibitor [AI]/palbociclib or everolimus) indicating an endocrine-refractory disease